PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025

Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, from 25 to 30 April.

In addition to its proprietary Amanitin-based ADC technology, Heidelberg Pharma has developed a diverse ADC toolbox designed to overcome tumor resistance through multiple mechanisms, enabling targeted treatment across various cancer types.

Dr. Sarah-Jane Neuberth will present preclinical findings on HDP-201, Heidelberg Pharma´s novel Exatecan-based, multimeric linker ADC, called ETAC technology, which is being developed for the treatment of colorectal cancer. The findings indicate target-specific potency, strong anti-tumor efficacy, and high tolerability.

Dr. Pablo Ruedas Batuecas will demonstrate the potential of computational modeling for optimizing NAMPT inhibitors (NAMPTi) designed in silico as payloads and as a mode of action (MOA) in ADC technology. This novel technology approach has the potential to overcome the current limitations of cancer therapies by targeting both dividing and non-dividing cancer cells.

AACR Annual Meeting 2025

Details of the conference and presentations are as follow:

Poster: HDP-201 – a novel multimeric linker exatecan-based ADC targeting Guanylyl cyclase C (GCC) for treatment of gastrointestinal malignancies

The ETAC HDP-201 is directed against the surface protein GCC (guanylyl cyclase C), which is highly overexpressed in gastrointestinal malignancies, including gastric and colorectal cancers.

HDP-201 showed potent anti-tumor efficacy in preclinical models, including complete tumor remission of GCC-expressing CDX models and significant inhibition of tumor growth in gastrointestinal PDX models. A single intravenous dose of 60 mg/kg of HDP-201 was well tolerated in cynomolgus monkeys, with no severe toxicity.

These findings underscore the potential of HDP-201 as a promising new therapeutic option for GCC-positive gastrointestinal malignancies.

Talk (Minisymposium): In silico optimized NAMPT inhibitor for targeted delivery by ADC as novel therapeutic modality for treatment of liquid and solid malignancies

Nearly half of the US Food and Drug Administration (FDA) approved ADCs are based on microtubule inhibitors, that selectively target dividing cancer cells but fail to eradicate non-dividing tumor stem cells, potentially leading to resistance and tumor relapse.

Inhibition of NAMPT, the rate-limiting enzyme in the salvage biosynthetic pathway of NAD+ starting from nicotinamide, induces cell death due to energy shortage in both dividing and non-dividing cell populations. This is a promising approach to overcome current therapy limitations by utilizing novel payloads.  

ADCs based on in silico designed NAMPTi as payloads show promising in vitro and in vivo results, highlighting the potential of NAMPT inhibition as an emerging MOA in ADC technology that enhances the targeted drug delivery to different cell lines.